<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39365795</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2767-3375</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PLOS global public health</Title><ISOAbbreviation>PLOS Glob Public Health</ISOAbbreviation></Journal><ArticleTitle>From barriers to opportunities from COVID-19 pandemic: Stakeholder perspectives on cervical cancer screening programs in LMICs of the Asia-Pacific region.</ArticleTitle><Pagination><StartPage>e0003768</StartPage><MedlinePgn>e0003768</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0003768</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pgph.0003768</ELocationID><Abstract><AbstractText>Cervical cancer is preventable, yet it remains the fourth most common cancer in women globally. The highest incidence and mortality occur in low- and middle-income countries (LMICs), where over 70% of women have never been screened, and 58% of the cases are in Asia. While the COVID-19 pandemic caused significant disruptions to cervical screening programs, particularly for LMICs, there were opportunities that emerged from the pandemic that were enablers of program recovery. Stakeholders played key roles in materialising strategy into implementation. Therefore, in this study, we examined the barriers and facilitators to implementing recovery strategies from the stakeholders' perspectives. We interviewed fifteen stakeholders from nine LMICs in the Asia-Pacific region directly involved in the implementation of the cervical screening program. A total of 23 barriers and 21 facilitators were identified, of which seven barriers and nine facilitators related directly to the pandemic. Pandemic-related barriers included movement restrictions, resource diversion, cancelled campaigns and training, deprioritisation of HPV prevention efforts, and a reduced health workforce. Stakeholders concurred that most barriers had predated the pandemic and remained as the pandemic eased. Conversely, the pandemic introduced facilitators such as means for targeted campaigns, improved understanding of viruses, accessible training with online platforms, better PCR testing capabilities, a shift in the government's position towards preventive health services, and openness to HPV testing and self-swabs. The emerging facilitators offered opportunities to address some of the persistent barriers, such as limited cervical cancer awareness and insufficient healthcare providers in screening programs. However, effective implementation of these emerging facilitators requires improved communication and collaboration between policymakers and implementers to accelerate the recovery of screening programs in LMICs. Further work is necessary to align emerging facilitators with the health system goals and resource settings of each country in turning these opportunities into actions.</AbstractText><CopyrightInformation>Copyright: © 2024 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jieying</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3322-1817</Identifier><AffiliationInfo><Affiliation>Asia Pacific HPV Coalition.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail-Pratt</LastName><ForeName>Ida</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3524-7965</Identifier><AffiliationInfo><Affiliation>Asia Pacific HPV Coalition.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Society for Colposcopy &amp; Cervical Pathology of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machalek</LastName><ForeName>Dorothy A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumarasamy</LastName><ForeName>Suresh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Asia Pacific HPV Coalition.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gleneagles Hospital Penang, George Town, Pulau Pinang, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garland</LastName><ForeName>Suzanne M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Asia Pacific HPV Coalition.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Women's Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLOS Glob Public Health</MedlineTA><NlmUniqueID>9918283779606676</NlmUniqueID><ISSNLinking>2767-3375</ISSNLinking></MedlineJournalInfo><CoiStatement>We have read the journal’s policy and the authors of this manuscript have the following competing interests: SMG is supported by NHMRC APP1197951 Leadership Investigator grant level 3, a member of the advisory board for the nine-valent HPV vaccine of Merck, received an educational grant from Merck for study on HPV and young women through her institution and received Merck lecture fees. SK has served on advisory boards of both Merck &amp; GSK and has received Merck and Roche lecture fees. IIP has received Roche and MSD lecture fees. DAM has received grants from Seqirus, non-financial support and honoraria from MSD, and non-financial support from Roche Diagnostics, not related to this manuscript. LJ has received honorarium from Abbott.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39365795</ArticleId><ArticleId IdType="pmc">PMC11451976</ArticleId><ArticleId IdType="doi">10.1371/journal.pgph.0003768</ArticleId><ArticleId IdType="pii">PGPH-D-24-01058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al.. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. The Lancet Global Health. 2023;11: e197–e206. doi: 10.1016/S2214-109X(22)00501-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00501-0</ArticleId><ArticleId IdType="pmc">PMC9848409</ArticleId><ArticleId IdType="pubmed">36528031</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al.. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. The Lancet Global Health. 2022;10: e1115–e1127. doi: 10.1016/S2214-109X(22)00241-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00241-8</ArticleId><ArticleId IdType="pmc">PMC9296658</ArticleId><ArticleId IdType="pubmed">35839811</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale DB, Teixeira JC, Bragança JF, Derchain S, Sarian LO, Zeferino LC. Elimination of cervical cancer in low‐ and middle‐income countries: Inequality of access and fragile healthcare systems. Int J Gynecol Obstet. 2021;152: 7–11. doi: 10.1002/ijgo.13458</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.13458</ArticleId><ArticleId IdType="pubmed">33128771</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckett R, Feldman S, Woo YL, Moscicki A-B, Giuliano AR, De Sanjosé S, et al.. COVID-19 as a catalyst for reimagining cervical cancer prevention. eLife. 2023;12: e86266. doi: 10.7554/eLife.86266</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86266</ArticleId><ArticleId IdType="pmc">PMC10171861</ArticleId><ArticleId IdType="pubmed">37070731</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Cervical Cancer Elimination Initiative: from call to action to global movement. 2023 May p. 14. Available: https://www.who.int/publications/m/item/who-cervical-cancer-elimination-initiative—from-call-to-action-to-global-movement</Citation></Reference><Reference><Citation>Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32: 795–808. doi: 10.1097/QAD.0000000000001765</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001765</ArticleId><ArticleId IdType="pmc">PMC5854529</ArticleId><ArticleId IdType="pubmed">29369827</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivacsy S, Bayingana A, Binagwaho A. Affordable human papillomavirus screening needed to eradicate cervical cancer for all. The Lancet Global Health. 2019;7: e1605–e1606. doi: 10.1016/S2214-109X(19)30423-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(19)30423-1</ArticleId><ArticleId IdType="pubmed">31708136</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. World Health Organization; 2020. Available: https://www.who.int/publications-detail-redirect/9789240014107</Citation></Reference><Reference><Citation>Lee J, Ismail-Pratt I, Machalek DA, Kumarasamy S, Garland SM. The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (LMICs) following COVID-19 disruptions. Preventive Medicine Reports. 2023;35: 102291. doi: 10.1016/j.pmedr.2023.102291</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2023.102291</ArticleId><ArticleId IdType="pmc">PMC10307672</ArticleId><ArticleId IdType="pubmed">37455756</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV. Human Papillomavirus Vaccination After COVID-19. JNCI Cancer Spectrum. 2021;5: pkab011. doi: 10.1093/jncics/pkab011</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jncics/pkab011</ArticleId><ArticleId IdType="pmc">PMC7962726</ArticleId><ArticleId IdType="pubmed">33748668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavi. Gavi Annual Progress Report 2020. Gavi; 2021 Sep.</Citation></Reference><Reference><Citation>World Health Organization. Progress and challenges with Achieving Universal Immunization Coverage. World Health Organization; 2022. Available: https://www.who.int/publications/m/item/progress-and-challenges</Citation></Reference><Reference><Citation>Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al.. Cross‐sectional survey of the impact of the COVID‐19 pandemic on cancer screening programs in selected low‐ and middle‐income countries: Study from the IARC COVID‐19 impact study group. Int J Cancer. 2021;149: 97–107. doi: 10.1002/ijc.33500</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.33500</ArticleId><ArticleId IdType="pmc">PMC8014228</ArticleId><ArticleId IdType="pubmed">33533501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas E, Murillo R, Arrossi S, Bárcena M, Chami Y, Nessa A, et al.. Quantification of impact of COVID-19 pandemic on cancer screening programmes -a case study from Argentina, Bangladesh, Colombia, Morocco, Sri Lanka and Thailand. Epidemiology; 2023. Feb. doi: 10.7554/eLife.86527</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86527</ArticleId><ArticleId IdType="pmc">PMC10188105</ArticleId><ArticleId IdType="pubmed">37191660</ArticleId></ArticleIdList></Reference><Reference><Citation>Michie S, Van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implementation Sci. 2011;6: 42. doi: 10.1186/1748-5908-6-42</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-6-42</ArticleId><ArticleId IdType="pmc">PMC3096582</ArticleId><ArticleId IdType="pubmed">21513547</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins L, Francis J, Islam R, O’Connor D, Patey A, Ivers N, et al.. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implementation Sci. 2017;12: 77. doi: 10.1186/s13012-017-0605-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13012-017-0605-9</ArticleId><ArticleId IdType="pmc">PMC5480145</ArticleId><ArticleId IdType="pubmed">28637486</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton MQ. Two Decades of Developments in Qualitative Inquiry: A Personal, Experiential Perspective. Qualitative Social Work. 2002;1: 261–283. doi: 10.1177/1473325002001003636</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1473325002001003636</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmeer K. Stakeholder Analysis Guidelines. Policy Toolkit for Strengthening Health Sector Reform. 2000.</Citation></Reference><Reference><Citation>Kung T-PH, Gordon JR, Abdullahi A, Barve A, Chaudhari V, Kosambiya JK, et al.. “My husband says this: If you are alive, you can be someone…”: Facilitators and barriers to cervical cancer screening among women living with HIV in India. Cancer Causes Control. 2019;30: 365–374. doi: 10.1007/s10552-019-01145-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-019-01145-7</ArticleId><ArticleId IdType="pmc">PMC6461359</ArticleId><ArticleId IdType="pubmed">30809741</ArticleId></ArticleIdList></Reference><Reference><Citation>McSherry LA, Dombrowski SU, Francis JJ, Murphy J, Martin CM, O’Leary JJ, et al.. ‘It’s a can of worms’: understanding primary care practitioners’ behaviours in relation to HPV using the theoretical domains framework. Implementation Sci. 2012;7: 73. doi: 10.1186/1748-5908-7-73</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1748-5908-7-73</ArticleId><ArticleId IdType="pmc">PMC3523072</ArticleId><ArticleId IdType="pubmed">22862968</ArticleId></ArticleIdList></Reference><Reference><Citation>Abiodun OA, Olu-Abiodun OO, Sotunsa JO, Oluwole FA. Impact of health education intervention on knowledge and perception of cervical cancer and cervical screening uptake among adult women in rural communities in Nigeria. BMC Public Health. 2014;14: 814. doi: 10.1186/1471-2458-14-814</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-814</ArticleId><ArticleId IdType="pmc">PMC4133628</ArticleId><ArticleId IdType="pubmed">25103189</ArticleId></ArticleIdList></Reference><Reference><Citation>Okunowo AA, Daramola ES, Soibi-Harry AP, Ezenwankwo FC, Kuku JO, Okunade KS, et al.. Women’s knowledge of cervical cancer and uptake of Pap smear testing and the factors influencing it in a Nigerian tertiary hospital. Journal of Cancer Research and Practice. 2018;5: 105–111. doi: 10.1016/j.jcrpr.2018.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrpr.2018.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozar T, Nagvekar R, Rohrer C, Dube Mandishora RS, Ivanus U, Fitzpatrick MB. Cervical Cancer Screening Postpandemic: Self-Sampling Opportunities to Accelerate the Elimination of Cervical Cancer. IJWH. 2021;Volume 13: 841–859. doi: 10.2147/IJWH.S288376</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJWH.S288376</ArticleId><ArticleId IdType="pmc">PMC8458024</ArticleId><ArticleId IdType="pubmed">34566436</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo YL, Gravitt P, Khor SK, Ng CW, Saville M. Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era. Preventive Medicine. 2021;144: 106294. doi: 10.1016/j.ypmed.2020.106294</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2020.106294</ArticleId><ArticleId IdType="pmc">PMC7931730</ArticleId><ArticleId IdType="pubmed">33678225</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcedo MP, Varon ML, Phoolcharoen N, Osman N, David E, Rangeiro R, et al.. Building local capacity for cervical cancer prevention in low resource settings: Changing strategy during the COVID-19 pandemic. J Glob Health. 2021;11: 03044. doi: 10.7189/jogh.11.03044</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.11.03044</ArticleId><ArticleId IdType="pmc">PMC7956015</ArticleId><ArticleId IdType="pubmed">33763214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chargari C, Arbyn M, Leary A, Abu-Rustum NR, Basu P, Bray F, et al.. Increasing global accessibility to high-level treatments for cervical cancers. Gynecologic Oncology. 2022;164: 231–241. doi: 10.1016/j.ygyno.2021.10.073</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2021.10.073</ArticleId><ArticleId IdType="pmc">PMC9496636</ArticleId><ArticleId IdType="pubmed">34716024</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghavi K, Mandiriri A, Shamu T, Rohner E, Bütikofer L, Asangbeh S, et al.. Cervical Cancer Screening Cascade for women living with HIV: A cohort study from Zimbabwe. Shrestha S, editor. PLOS Glob Public Health. 2022;2: e0000156. doi: 10.1371/journal.pgph.0000156</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgph.0000156</ArticleId><ArticleId IdType="pmc">PMC9974171</ArticleId><ArticleId IdType="pubmed">36860760</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro KM, Gage JC, Rosenbaum AJ, Ditzian LR, Maza M, Scarinci IC, et al.. Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program. BMC Public Health. 2015;15: 1058. doi: 10.1186/s12889-015-2360-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-015-2360-7</ArticleId><ArticleId IdType="pmc">PMC4609068</ArticleId><ArticleId IdType="pubmed">26474762</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu P, Lucas E, Zhang L, Muwonge R, Murillo R, Nessa A. Leveraging vertical COVID-19 investments to improve monitoring of cancer screening programme–A case study from Bangladesh. Preventive Medicine. 2021;151: 106624. doi: 10.1016/j.ypmed.2021.106624</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2021.106624</ArticleId><ArticleId IdType="pmc">PMC9755639</ArticleId><ArticleId IdType="pubmed">34023359</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson-Jones D, Lees S, Mwanga J, Neke N, Changalucha J, Broutet N, et al.. Feasibility and acceptability of delivering adolescent health interventions alongside HPV vaccination in Tanzania. Health Policy Plan. 2016;31: 691–699. doi: 10.1093/heapol/czv119</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/heapol/czv119</ArticleId><ArticleId IdType="pmc">PMC4916316</ArticleId><ArticleId IdType="pubmed">26768827</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO guideline on health policy and system support to optimize community health worker programmes. [cited 31 Jul 2023]. Available: https://www.who.int/publications-detail-redirect/9789241550369</Citation><ArticleIdList><ArticleId IdType="pubmed">30431747</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Donovan J, O’Donovan C, Nagraj S. The role of community health workers in cervical cancer screening in low-income and middle-income countries: a systematic scoping review of the literature. BMJ Glob Health. 2019;4: e001452. doi: 10.1136/bmjgh-2019-001452</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2019-001452</ArticleId><ArticleId IdType="pmc">PMC6528769</ArticleId><ArticleId IdType="pubmed">31179040</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Human papillomavirus (HPV) nucleic acid amplification tests (NAATs) to screen for cervical pre-cancer lesions and prevent cervical cancer: policy brief. Geneva: World Health Organization; 2022. Available: https://apps.who.int/iris/handle/10665/352495</Citation></Reference><Reference><Citation>Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al.. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database of Systematic Reviews. 2017;2018. doi: 10.1002/14651858.CD008587.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008587.pub2</ArticleId><ArticleId IdType="pmc">PMC6483676</ArticleId><ArticleId IdType="pubmed">28796882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogilvie GS, Van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al.. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. JAMA. 2018;320: 43. doi: 10.1001/jama.2018.7464</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.7464</ArticleId><ArticleId IdType="pmc">PMC6583046</ArticleId><ArticleId IdType="pubmed">29971397</ArticleId></ArticleIdList></Reference><Reference><Citation>Taghavi K, Moono M, Asangbeh S, Gillett G, Pascoe M, Manasyan A. Strengthening global commitment to eliminating cervical cancer: What lessons from the past can we apply to the future? Journal of Global Health. 2020;10: 020385. doi: 10.7189/jogh.10.020385</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.10.020385</ArticleId><ArticleId IdType="pmc">PMC7648905</ArticleId><ArticleId IdType="pubmed">33214893</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin MB, Garcia PJ, Saldarriaga EM, Fiestas JL, Ásbjörnsdóttir KH, Iribarren SJ, et al.. Cost of community-based human papillomavirus self-sampling in Peru: A micro-costing study. The Lancet Regional Health—Americas. 2022;8: 100160. doi: 10.1016/j.lana.2021.100160</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2021.100160</ArticleId><ArticleId IdType="pmc">PMC9075528</ArticleId><ArticleId IdType="pubmed">35528707</ArticleId></ArticleIdList></Reference><Reference><Citation>Creagh NS, Boyd LAP, Bavor C, Zammit C, Saunders T, Oommen AM, et al.. Self-Collection Cervical Screening in the Asia-Pacific Region: A Scoping Review of Implementation Evidence. JCO Global Oncology. 2023; e2200297. doi: 10.1200/GO.22.00297</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/GO.22.00297</ArticleId><ArticleId IdType="pmc">PMC10166429</ArticleId><ArticleId IdType="pubmed">36724416</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization AAFC. External Evaluation of the Access To COVID-19 Tools Accelerator (ACT-A). 2022 Oct. Available: https://www.who.int/publications/m/item/external-evaluation-of-the-access-to-covid-19-tools-accelerator-(act-a)</Citation></Reference><Reference><Citation>Gravitt PE, Silver MI, Hussey HM, Arrossi S, Huchko M, Jeronimo J, et al.. Achieving equity in cervical cancer screening in low- and middle-income countries (LMICs): Strengthening health systems using a systems thinking approach. Preventive Medicine. 2021;144: 106322. doi: 10.1016/j.ypmed.2020.106322</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2020.106322</ArticleId><ArticleId IdType="pubmed">33678230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorsters A, Bosch FX, Poljak M, Waheed D-N, Stanley M, Garland SM. HPV prevention and control–The way forward. Preventive Medicine. 2022;156: 106960. doi: 10.1016/j.ypmed.2022.106960</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2022.106960</ArticleId><ArticleId IdType="pmc">PMC8772134</ArticleId><ArticleId IdType="pubmed">35065979</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaganda A, Lasebikan N, Garton EM, Kithaka B, Cira MK. Neglected Elements of Cancer Control During The COVID-19 Pandemic in Africa: Call for Action from 2019–2020 African Cancer Research and Control ECHO Programme. Cancer Epidemiology, Biomarkers &amp; Prevention. 2021;30: 11–11. doi: 10.1158/1538-7755.ASGCR21-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7755.ASGCR21-11</ArticleId></ArticleIdList></Reference><Reference><Citation>Marlow LAV, Waller J, Wardle J. Barriers to cervical cancer screening among ethnic minority women: a qualitative study. J Fam Plann Reprod Health Care. 2015;41: 248–254. doi: 10.1136/jfprhc-2014-101082</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jfprhc-2014-101082</ArticleId><ArticleId IdType="pmc">PMC4621371</ArticleId><ArticleId IdType="pubmed">25583124</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam RM, Billah B, Hossain MN, Oldroyd J. Barriers to Cervical Cancer and Breast Cancer Screening Uptake in Low-Income and Middle-Income Countries: A Systematic Review. Asian Pac J Cancer Prev. 2017;18. doi: 10.22034/APJCP.2017.18.7.1751</Citation><ArticleIdList><ArticleId IdType="doi">10.22034/APJCP.2017.18.7.1751</ArticleId><ArticleId IdType="pmc">PMC5648375</ArticleId><ArticleId IdType="pubmed">28749101</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Naggar RA, Low W, Isa Z. Knowledge and Barriers Towards Cervical Cancer Screening Among Young Women in Malaysia.</Citation><ArticleIdList><ArticleId IdType="pubmed">21133593</ArticleId></ArticleIdList></Reference><Reference><Citation>Black E, Hyslop F, Richmond R. Barriers and facilitators to uptake of cervical cancer screening among women in Uganda: a systematic review. BMC Women’s Health. 2019;19: 108. doi: 10.1186/s12905-019-0809-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-019-0809-z</ArticleId><ArticleId IdType="pmc">PMC6688246</ArticleId><ArticleId IdType="pubmed">31399092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzistamatiou K, Vrekoussis T, Tsertanidou A, Moysiadis T, Mouchtaropoulou E, Pasentsis K, et al.. Acceptability of Self-Sampling for Human Papillomavirus-Based Cervical Cancer Screening. J Womens Health (Larchmt). 2020;29: 1447–1456. doi: 10.1089/jwh.2019.8258</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2019.8258</ArticleId><ArticleId IdType="pubmed">32757997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath Mulki A, Withers M. Human Papilloma Virus self-sampling performance in low- and middle-income countries. BMC Women’s Health. 2021;21: 12. doi: 10.1186/s12905-020-01158-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-020-01158-4</ArticleId><ArticleId IdType="pmc">PMC7789658</ArticleId><ArticleId IdType="pubmed">33407355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mekuria SF, Timmermans S, Borgfeldt C, Jerkeman M, Johansson P, Linde DS. HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC: a systematic review and meta-analysis. Syst Rev. 2023;12: 103. doi: 10.1186/s13643-023-02252-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02252-y</ArticleId><ArticleId IdType="pmc">PMC10286394</ArticleId><ArticleId IdType="pubmed">37349822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravington A, Chen H, Dyson J, Jones L, Dalgliesh C, Bryan A, et al.. Translating qualitative data into intervention content using the Theoretical Domains Framework and stakeholder co-design: a worked example from a study of cervical screening attendance in older women. BMC Health Serv Res. 2022;22: 610. doi: 10.1186/s12913-022-07926-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-022-07926-2</ArticleId><ArticleId IdType="pmc">PMC9074234</ArticleId><ArticleId IdType="pubmed">35524217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>